0.4135
AEON Biopharma Inc. 주식(AEON)의 최신 뉴스
AEON Biopharma gets NYSE American nod for compliance plan - Investing.com
AEON Biopharma gets NYSE American nod for compliance plan By Investing.com - Investing.com India
AEON Biopharma Says NYSE American Accepts Plan to Regain Compliance - marketscreener.com
AEON Biopharma Receives Acceptance from NYSE American to Regain Compliance with Listing Standards - Nasdaq
AEON Biopharma Announces NYSE American Acceptance of Plan to Regain Listing Compliance - The Manila Times
NYSE American Grants AEON Biopharma 2-Year Lifeline to Meet Listing Requirements - Stock Titan
What was AEON Biopharma Inc (AEON)’s performance in the last session? - uspostnews.com
Analyzing the Impact of Earnings Reports on AEON Biopharma Inc Inc. (AEON) Price Performance - investchronicle.com
Who’s Hired? Botox Biosimilar Developer Aeon Takes CEO From Rival Revance - insights.citeline.com
AEON Biopharma, Inc. Announces Executive Changes, Effective as of April 4, 2025 - marketscreener.com
AEON Biopharma announces CEO appointment - MSN
AEON Biopharma names Rob Bancroft as new CEO By Investing.com - Investing.com South Africa
Aeon Biopharma Names Robert Bancroft CEO - marketscreener.com
AEON Biopharma Appoints New CEO Robert Bancroft - TipRanks
Aeon Biopharma (AEON) Appoints Rob Bancroft as New CEO | AEON Stock News - GuruFocus
AEON Biopharma Appoints Rob Bancroft as CEO - MarketWatch
AEON Biopharma Reports Inducement Grants Under NYSE American LLC Company Guide Section 711 - The Manila Times
AEON Biopharma Appoints Industry Veteran Rob Bancroft as Chief Executive Officer - The Manila Times
AEON Biopharma names Rob Bancroft as new CEO - Investing.com
AEON Biopharma Appoints New CEO Rob Bancroft: Inside the $1M+ Executive Compensation Deal - Stock Titan
Former Revance Therapeutics Leader Takes AEON Helm: Inside the Race to Challenge BOTOX's $3B Market - Stock Titan
AEON Biopharma (NASDAQ:AEON) Trading 2.5% Higher – Time to Buy? - Defense World
AEON Biopharma announces new interim CEO and CFO By Investing.com - Investing.com Australia
AEON Biopharma Appoints Jost Fischer as Interim CEO - TipRanks
AEON Biopharma announces new interim CEO and CFO - Investing.com
Trading Day Triumph: AEON Biopharma Inc (AEON) Ends at 0.42, a -10.60 Surge/Plunge - DWinneX
Aesthetic Medicine Powerhouse: BOTOX Veteran Takes Helm at Jeune Aesthetics - Stock Titan
AEON Biopharma Inc (AEON) Stock: The Story of a 52-Week Stock Range - investchronicle.com
AEON Biopharma’s Strategic Progress and Financial Turnaround - TipRanks
Mineralys, Sana, Aeon: These 3 Biotech Stocks Saw The Sharpest Retail Interest Spike In Q1 - NewsBreak: Local News & Alerts
AEON Biopharma announces leadership change amid growth strategy By Investing.com - Investing.com Philippines
Aeon Biopharma CEO to Step Down Next Week - Orange County Business Journal
AEON Biopharma Announces CEO Transition - The Manila Times
AEON Biopharma CEO Marc Forth to Resign; Board Chairman Jost Fischer Is Interim CEO - MarketScreener
AEON Biopharma announces leadership change amid growth strategy - Investing.com
AEON Biopharma Announces CEO Resignation and Interim Appointment - TipRanks
Leadership Shift at AEON Biopharma: CEO Exit Won't Delay Critical FDA Timeline - Stock Titan
AEON Eyeing FDA Meeting On Botox Biosimilar By The End Of 2025 - insights.citeline.com
AEON Biopharma Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update - The Manila Times
AEON Biopharma, Inc. Advances Biosimilar Development for ABP-450 with FDA Meeting Planned for 2025 - Nasdaq
AEON's $20M Cash Injection Powers Game-Changing BOTOX Alternative Development - Stock Titan
AEON Biopharma (NASDAQ:AEON) Stock Price Down 7.6% – Should You Sell? - Defense World
12 Health Care Stocks Moving In Thursday's Pre-Market Session - Benzinga
Understanding AEON’s financial ratios: A beginner’s guide - US Post News
AEON Biopharma Releases New Corporate Presentation - TipRanks
AEON Biopharma : Corporate Presentation -March 10, 2025 at 06:26 am EDT - Marketscreener.com
AEON Biopharma, Inc. to Participate in the Leerink Global Healthcare Conference - The Manila Times
AEON CEO to Showcase Botulinum Toxin Pipeline at Major Healthcare Conference - StockTitan
AIM ImmunoTech, PepGen, Aeon, Tiziana, Moleculin: 5 Biotech Stocks That Led Retail Message Growth Last Week - Asianet Newsable
Cervical Dystonia Market Expected to Experience Major Growth - openPR
AEON stock touches 52-week low at $0.76 amid market shifts - Investing.com
AEON Biopharma, Inc. Deloitte, Inc. Announces Update of Phase 2 Double Blind Study of ABP-450 in the Treatment of Migraine - Marketscreener.com
AEON Biopharma Announces Preliminary Top-Line Results from Phase 2 Interim Analysis of ABP-450 in the Preventive Treatment of Chronic Migraine -May 03, 2024 at 07:00 am EDT - MarketScreener
AEON Biopharma, Inc. Announces Executive Changes -May 16, 2024 at 04:28 pm EDT - marketscreener.com
AEON Biopharma, Inc. Announces Strategic Reprioritization to Pursue A Biosimilar Pathway for ABP-450 - Marketscreener.com
AEON Biopharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - MarketScreener
자본화:
|
볼륨(24시간):